Bayer Aktiengesellschaft (BAYRY): Price and Financial Metrics

Bayer Aktiengesellschaft (BAYRY): $15.73

-0.24 (-1.47%)

POWR Rating

Component Grades













BAYRY Stock Price Chart Interactive Chart >

Price chart for BAYRY

BAYRY Price/Volume Stats

Current price $15.73 52-week high $21.05
Prev. close $15.97 52-week low $11.65
Day low $15.64 Volume 217,500
Day high $15.78 Avg. volume 446,214
50-day MA $16.36 Dividend yield 2.61%
200-day MA $15.37 Market Cap 58.68B

Bayer Aktiengesellschaft (BAYRY) Company Bio

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

BAYRY Latest News Stream

Event/Time News Detail
Loading, please wait...

BAYRY Latest Social Stream

Loading social stream, please wait...

View Full BAYRY Social Stream

Latest BAYRY News From Around the Web

Below are the latest news stories about Bayer Aktiengesellschaft that investors may wish to consider to help them evaluate BAYRY as an investment opportunity.

Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials

Bayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative movement disorder is recruiting patients. Bayer’s subsidiary BlueRock Therapeutics’s trial will eventually enroll 10 participants. Patients will have dopamine-producing cells surgically implanted into a part of the brain called the putamen. The trial will primarily examine the safety and tolerability of DA01 cell transplantation a year after the pro

Yahoo | June 8, 2021

Novartis (NVS) Posts Positive Data on Kidney Disease Candidate

Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

Yahoo | June 7, 2021

Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals

Bayer AG (OTC: BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the German drugmaker's pipeline. Bayer will pay an undisclosed sum for Noria Therapeutics and PSMA Therapeutics, built around radiotherapy research from the Weill Cornell Medical College in NYC. The deal is centered around an actinium-225 labeled prostate-specific membrane antigen (PSMA) small molecule currently in pre-IND studies for prostate cancer. Bayer has its portf

Yahoo | June 3, 2021

J&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal Rejection

The U.S. Supreme Court rejects J&J's (JNJ) appeal against a lower court verdict of $2.1 billion in damages in a litigation related to its talc-based baby powder.

Yahoo | June 2, 2021

Bayer to review Roundup's future in U.S. after court setback

Bayer (BAYRY) says it will evaluate whether to continue using glyphosate in its Roundup weedkiller in the residential U.S. market after a judge today rejected its plan to settle future claims alleging the herbicide causes cancer.Bayer also says it will abandon attempts at a court-approved solution to address its future...

Seeking Alpha | May 27, 2021

Read More 'BAYRY' Stories Here

BAYRY Price Returns

1-mo -7.63%
3-mo 1.33%
6-mo 10.16%
1-year -16.28%
3-year -39.91%
5-year -31.31%
YTD 8.71%
2020 -24.50%
2019 19.17%
2018 -42.40%
2017 21.36%
2016 -15.03%

BAYRY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full BAYRY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8056 seconds.